Pathophysiology of endothelin in the cardiovascular system

Annual Review of Physiology

Volumn 61, Issue , 1999, Pages 391-415

  Miyauchi, Takashi ^a   Masaki, Tomoh ^b  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

Author keywords

Endothelin receptor; Heart failure; Pharmacology; Receptor antagonist; Signal transduction

Indexed keywords

2 [[2 [[2 [[(HEXAHYDRO 1H AZEPIN 1 YL)CARBONYL]AMINO] 4 METHYLPENTANOYL]AMINO] 3 (1 METHYL 1H INDOL 3 YL)PROPIONYL]AMINO] 3 (2 PYRIDYL)PROPIONIC ACID; 3 (2 CARBOXYMETHOXY 4 METHOXYPHENYL) 1 (3,4 METHYLENEDIOXYPHENYL) 5 PROPOXY 2 INDANCARBOXYLIC ACID; 3 BENZYL 4 (4 METHOXYPHENYL) 2 (3,4 METHYLENEDIOXYPHENYL) 4 OXO 2 BUTENOIC ACID; 4 (4 METHOXYPHENYL) 2 (3,4 METHYLENEDIOXYPHENYL) 4 OXO 3 (3,4,5 TRIMETHOXYBENZYL) 2 BUTENOIC ACID; 4 TERT BUTYL N [6 (2 HYDROXYETHOXY) 5 (3 METHOXYPHENOXY) 4 PYRIMIDINYL]BENZENESULFONAMIDE; 5 DIMETHYLAMINO N (3,4 DIMETHYL 5 ISOXAZOLYL) 1 NAPHTHALENESULFONAMIDE; BOSENTAN; CARVEDILOL; CYCLO(DEXTRO GLUTAMYLALANYL DEXTRO ALLO ISOLEUCYLLEUCYL DEXTRO TRYPTOPHYL); CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); ENDOTHELIN 1; ENDOTHELIN CONVERTING ENZYME; ENDOTHELIN RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; IRL 2500; J 104121; L 751281; L 754142; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; N (HEXAHYDRO 1 AZEPINYLCARBONYL)LEUCYL(1 METHYL DEXTRO TRYPTOPHYL) DEXTRO TYROSINE; N [6 [2 (5 BROMOPYRIMIDIN 4 YL)] 4 (2 HYDROXY 1,1 DIMETHYLETHYL)]BENZENSULFONAMIDE SODIUM SESQUIHYDRATE; N ACETYLENDOTHELIN 1 [6-21][11,15 ALANINE]; PED 3512; SB 66861; SUCCINYLENDOTHELIN 1 [8-21][9 GLUTAMIC ACID 11,15 ALANINE]; T 0115; TAK 044; TTA 386; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; BRAIN VASOSPASM; DRUG POTENCY; DRUG RECEPTOR BINDING; ENZYME INHIBITION; HEART FAILURE; HUMAN; HYPERTENSION; MOLECULAR DYNAMICS; NONHUMAN; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN SYNTHESIS REGULATION; PULMONARY HYPERTENSION; RECEPTOR BLOCKING; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; ENDOTHELINS; HUMANS; KIDNEY DISEASES; RECEPTORS, ENDOTHELIN; SIGNAL TRANSDUCTION;

EID: 0033068028     PISSN: 00664278     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.physiol.61.1.391     Document Type: Review

References (186)

1. 1. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, et al. 1988. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332:411-15
2. 2. Inoue A, Yanagisawa M, Kimura S, Kasuya Y, Miyauchi T, et al. 1989. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc. Natl. Acad. Sci. USA 86:2863-67
3. 3. Takasaki C, Tamiya N, Bdolah A, Wollberg Z, Kochva E. 1988. Sarafotoxins S6: several isotoxins from Atractaspis engaddensis (burrowing asp) venom that affect the heart. Toxicon 26:543-48
4. 4. Sakurai T, Yanagisawa M, Inoue A, Ryan US, Kimura S, et al. 1991. cDNA cloning, sequence analysis and tissue distribution of rat preproendothelin-1 mRNA. Biochem. Biophys. Res. Commun. 175:44-47
5. 5. Masaki T, Vane JR, Vanhoutte PM. 1994. International union of pharmacology nomenclature of endothelin receptors. Pharmacol. Rev. 46:137-42
6. 6. Arai H, Hori S, Aramori I, Aramori I, Ohkub H, Nakanishi S. 1990. Cloning and expression of a cDNA encoding an endothelin receptor. Nature 348:730-32
7. 7. Sakurai T, Yanagisawa M, Takuwa Y, Miyazaki H, Kimura S, et al. 1990. Cloning of a cDNA encoding a non isopeptide selective subtype of the endothelin receptor. Nature 348:732-35
8. 8. Kurihara Y, Kurihara H, Suzuki H, Kodama T, Maemura K, et al. 1994. Elevated blood pressure and craniofacial abnormalities in mice deficient in endothelin-1. Nature 368:703-10
9. 9. Hosoda K, Hammer RE, Giad A, Richardson JA, Baynash AG, et al. 1994. Targeted and natural (piebald-lethal) mutations of endothelin-B receptor gene produce megacolon associated with spotted coat color in mice. Cell 79:1267-76
10. 10. Puffenberger EG, Hosoda K, Washington SS, Nakao K, deWit D, et al. 1994. A missense mutation of the endothelin-B-receptor gene in multigenic Hirschsprung's disease. Cell 79:1257-66
11. 11. Gronostajski RM. 1987. Site specific DNA binding of nuclear factor 1: effect of spacer region. Nucleic Acids Res. 15:5545-59
12. 12. Inoue A, Yanagisawa M, Takuwa Y, Mitsui Y, Kobayashi M, Masaki T. 1989. The human preproendothelin-1 gene: complete nucleotide sequence and regulation of expression. J. Biol. Chem. 264:14954-59
13. 13. Emori T, Hirata Y, Imai T, Ohta K, Kanno K, et al. 1992. Cellular mechanisms of thrombin on endothelin-1 biosynthesis and release in bovine endothelial cell. Biochem. Pharmacol. 44:2409-11
14. 14. Kurihara H, Yoshizumi M, Sugiyama T, Takaku F, Yanagisawa M, et al. 1989. Transforming growth factor beta stimulates the expression of endothelin mRNA from vascular endothelial cells. Biochem. Biophys. Res. Commun. 159:1435-40
15. 15. Marsden PA, Brenner BM. 1992. Transcriptional regulation of the endothelin gene by TNF alpha. Am. J. Physiol. 262: C854-61
16. 16. Maemura K, Kurihara H, Morita T, Hayashi Y, Yazaki Y. 1992. Production of endothelin-1 in vascular endothelial cells is regulated by factors associated with vascular injury. Gerontorogy 38 (Suppl. 1):29-35
17. 17. Marsden PA, Dorfman DM, Collins T, Brenner BM, Orkin SH, Ballermann BJ. 1991. Regulated expression of endothelin-1 in glomerular capillary endothelial cells. Am. J. Physiol. 261:F117-25
18. 18. Imai T, Hirata Y, Emori T, Yanagisawa M, Masaki T, Marumo F. 1992. Induction of endothelin-1 gene by angiotensin and vasopressin in endothelial cells. Hypertension 19:753-57
19. 19. Sharefki JB, Diamond SL, Eskin SG, McIntire LV, Fenbach CW. 1991. Fluid flow decreases preproendothelin mRNA levels and suppresses endothelin-1 peptide release in cultured human endothelial cells. J. Vasc. Surg. 14:1-9
20. 20. Malek A, Izumo S. 1992. Physiological fluid shear stress causes downregulation of endothelin-1 mRNA in bovine aortic endothelium. Am. J. Physiol. 263:C389-96
21. 21. Yoshizumi M, Kurihara H, Sugiyama T, Takaku F, Yanagisawa M, et al. 1989. Hemodynamic shear stress stimulates endothelin production by cultured endothelial cells. Biochem. Biophys. Res. Commun. 161:859-64
22. 22. Sumpio BE, Widmann MD. 1990. Enhanced production of endothelium-derived contracting factor by endothelial cells subjected to pulsatile stretch. Surgery 108:277-81
23. 23. Malek AM, Greene AL, Izumo S. 1993. Regulation of endothelin-1 gene by fluid shear stress is transcriptionally mediated and independent of protein kinase C and cAMP. Proc. Natl. Acad. Sci. USA 90:5999-6003
24. 24. Emori T, Hirata Y, Imai T, Eguchi S, Kanno K, Marumo F. 1993. Cellular mechanism of natriuretic peptides-induced inhibition of endothelin-l biosynthesis in rat endothelial cells. Endocrinology 133:2474-80
25. 25. Imai T, Hirata Y, Emori T, Marumo F. 1993. Heparin has an inhibitory effect on endothelin-1 synthesis and release by endothelial cells. Hypertension 21:353-58
26. 26. Kido T, Sawamura T, Hoshikawa H, D'Orleans-Juste P, Denault JB, et al. 1997. Processing of proendothelin-1 at the C-terminus of big endothelin-1 is essential for proteolysis by endothelin-converting enzyme-1 in vivo. Eur. J. Biochem. 244:520-26
27. 27. Matsumura Y, Hisaki K, Takaoka M, Morimoto S. 1990. Phosphoramidon, a metalloprotase inhibitor, suppresses the hypertensive effect of big endothelin-1. Eur. J. Pharmacol. 185:103-6
28. 28. Gardiner SM, Compton AM, Kemp PA, Bennett T. 1991. The effects of phosphoramidon on the regional haemodynamic responses to human proendothelin (1-38) in conscious rats. Br. J. Pharmacol. 103:2009-15
29. 29. Takahashi T, Matsushita Y, Iijima Y, Tanzawa K. 1993. Purification and characterization of endothelin-converting enzyme from rat lung. J. Biol. Chem. 268:21394-98
30. 30. Shimada K, Takahashi M, Tanzawa K. 1994. Cloning and functional expression of endothelin-converting enzyme from rat endothelial cells. J. Biol. Chem. 269:18275-78
31. 31. Emoto N, Yanagisawa M. 1995. Endothelin-converting enzyme-2 is a membrane-bound, phosphoramidon-sensitive metalloprotease with acidic pH optimum. J. Biol. Chem. 279:16262-68
32. 32. Lin HY, Kaji EH, Winkel GK, Ives HE, Lodish HF. 1991. Cloning and functional expression of a vascular smooth muscle endothelin receptor. Proc. Natl. Acad. Sci. USA 88:3185-89
33. 33. Elshourbagy NA, Lee JA, Korman DR, Nuthalaganti P, Sylvester DR, et al. 1992. Molecular cloning of the major endothelin receptor subtype in porcine cerebellum. Mol. Pharmacol. 41:465-73
34. 34. Hosoda K, Nakao K, Tamura N, Arai H, Ogawa Y, et al. 1992. Organization, structure, chromosomal assignment, and expression of the gene encoding the human endothelin A receptor. J. Biol. Chem. 267:18797-804
35. B endothelin receptor. Biochem. Biophys. Res. Commun. 178:656-63
36. 36. Sakurai T, Yanagisawa M, Masaki T. 1992. Molecular characterization of endothelin receptors. Trends Pharmacol. Sci. 13:103-8
37. 37. Hirata Y, Yoshimi H, Takaichi S, Yanagisawa M, Masaki T. 1988. Binding and receptor down regulation of a novel vasoconstrictor endothelin in cultured rat vascular smooth muscle cells. FEBS Lett. 239:13-17
38. 38. Devesly P, Phillips PE, Johns A, Rubanyi GM, Parker-Botelho LH. 1990. Receptor kinetics differ for endothelin 1 and endothelin 2 binding to Swiss 3T3 fibroblasts. Biochem. Biophys. Res. Commun. 172:126-34
39. 39. Thomas CP, Baldi E, Simonson MS, Kester M, Dunn MJ. 1991. Endothelin receptors and coupled GTP binding proteins in glomerular mesangial cells. J. Cardiovasc. Pharmacol. 17(Suppl. 7):S79-84
40. 40. Resink TJ, Scott-Burden T, Buhler FR. 1990. Activation of multiple signal transduction pathways by endothelin in cultured human vascular smooth muscle cells. Eur. J. Biochem. 189:415-21
41. B receptor mRNA is down-regulated by endothelin through decreasing the intracellular stability of mRNA molecules. Biochem. Biophys. Res. Commun. 186:342-47
42. B receptor subtype mRNA by angiotensin II in rat cardiomyocytes. Biochem. Biophys. Res. Commun. 194: 1282-87
43. A receptor mRNA and increases responsiveness to endothelin-1 of rat aortic smooth muscle cells in primary culture. Biochem. Biophys. Res. Commun. 188:719-26
44. 44. Nambi P, Pullen M, Wu HL, Nuthulaganti P, Elshourbagy N, Kumar C. 1992. Dexamethasone down-regulates the expression of endothelin receptors in vascular smooth muscle cells. J. Biol. Chem. 267: 19555-59
45. 45. Badr KF, Murray JJ, Breyer MD, Takahashi K, Inagami T, Harris RC. 1989. Mesangial cell, glomerular and renal vascular responses to endothelin in the rat kidney. Elucidation of signal transduction pathways. J. Clin. Invest. 83:336-42
46. 46. Takuwa Y, Kasuya Y, Takuwa N, Kudo M, Yanagisawa M, et al. 1990. Endothelin receptor is coupled to phospholipase C via a pertussis toxin insensitive guanine nucleotide binding regulatory protein in vascular smooth muscle cells. J. Clin. Invest. 85:653-58
47. 47. Simonson MS, Dunn MJ. 1990. Cellular signaling by peptides of the endothelin gene family. FASEB J. 4:2989-3000
48. 48. Silberberg SD, Poder TC, Lacerda A. 1989. Endothelin increases single channel calcium currents in coronary arterial smooth muscle cells. FEBS Lett. 247:68-72
49. 2+ channel in vascular smooth muscle. Proc. Natl. Acad. Sci. USA 86:3915-18
50. 2+-permeable nonselective cation channels by endothelin-1 in A7r5 cells. Br. J. Pharmacol. 124:1541-49
51. 51. Liu Y, Geisburhler B, Jones AW. 1992. Activation of multiple mechanisms including phopholipase D by endothelin-1 in rat aorta. Am. J. Physiol. 262:C941-46
52. 52. Griendling KK, Tsuda T, Alexander RW. 1989. Endothelin stimulates diacyglycerol accumulation and activates protein kinase C in cultured vascular smooth muscle cells. J. Biol. Chem. 264:8237-40
53. + exchange activation by endothelin in vascular smooth muscle cells. Am. J. Hypertens. 4:776-79
54. 54. Chua BH, Krebs CJ, Chua CC, Diglio CA. 1992. Endothelin stimulates protein synthesis in smooth muscle cells. Am. J. Physiol. 262:E412-16
55. 55. Bogoyevitch MA, Glennon PE, Sugden PH. 1993. Endothelin 1, phorbol esters and phenylephirine stimulate MAP kinase activities in ventricular cardiomyocytes. FEBS Lett. 317:271-75
56. 56. Simonson MS, John JM, Dunn MJ. 1992. Differential regulation of fos and jun gene expression and AP 1 cis element activity by endothelin isopeptides. Possible implication for mitogenic signaling by endothelin. J. Biol. Chem. 267:8643-49
57. 57. Simonson MS. 1993. Endothelins: multifunctional renal peptides. Physiol. Rev. 73:375-411
58. 58. Okazawa M, Shiraki T, Ninomiya H, Kobayashi S, Masaki T. 1998. Endothelin-induced apoptosis of A 375 human melanoma cells. J. Biol. Chem. 273: 12584-92
59. B. Am. J. Physiol. 267: C1130-35
60. 60. Sugawara F, Ninomiya H, Okamoto Y, Miwa S, Mazda O, et al. 1996. Endothelin-1-induced mitogenic responses of Chinese hamster ovary cells expressing human endothelin A: the role of a Wortmannin-sensitive signaling pathway. Mol. Pharmacol. 49:447-57
61. 61. Cazaubon S, Parker PJ, Strosberg AD, Couraud P-O. 1993. Endothlins stimulate tyrosine phosphorylation and activity of p42/mitogen-activated protein kinase in astrocytes. Biochem. J. 293:381-86
62. 62. Wang Y, Simonson MS, Pouysségur J, Dunn MJ. 1992. Endothelin rapidly stimulates mitogen-activated protein kinase activity in rat mesangial cells. Biochem. J. 287:589-94
63. 63. Cazaubon SM, Ramos-Morales F, Fischer S, Schweighoffer F, Strosberg AD, Couraud P-O. 1994. Endothelin induces tyrosine phosphorylation and GRB2 association of Shc in astrocytes. J. Biol. Chem. 269:24805-9
64. A) antagonist isolated from Streptomyces misakiensis. Biochem. Biophys. Res. Commun. 178:132-37
65. A receptor. Life Sci. 50:247-55
66. A selectivity. J. Med. Chem. 35:2139-42
67. B-mediated blood pressure responses in rats. J. Pharmacol. Exp. Ther. 270:728-33
68. 68. Aramori I, Nirei H, Shoubo M, Sogabe K, Nakamura K, et al. 1993. Subtype selectivity of a novel endothelin antagonist, FR 139317, for the two endothelin receptors in transfected Chinese hamster ovary cells. Mol. Pharmacol. 43:127-31
69. A receptors. Br. J. Pharmacol. 111:4-6
70. A receptor distribution. J. Cardiovasc. Pharmacol. 22(Suppl. 8):S128-31
71. B receptor. Cardiovasc. Drug. Rev. 11:253-70
72. 72. Ishikawa K, Ihara M, Noguchi K, Mase T, Mino N, et al. 1994. Biochemical and pharmacological profile of a potent and selective endothelin B-receptor antagonists, BQ-788. Proc. Natl. Acad. Sci. USA 91:4892-96
73. B-selective antagonist IRL 2500 in conscious spontaneously hypertensive and Wistar-Kyoto rats. J. Cardiovasc. Pharmacol. 26(Suppl. 3):S389-92
74. 74. Clozel M, Breu V, Burri K, Cassal JM, Fischli W, et al. 1993. Pathophysiological role of endothelin revealed by the first orally active endothelin receptor antagonist. Nature 365:759-61
75. 75. Clozel M, Breu V, Gray GA, Kalina B, Loffler BM, et al. 1994. Pharmacological characterization of bosentan, a new potent orally active nonpeptide endothelin antagonist. J. Pharmacol. Exp. Ther. 270:228-35
76. 76. Elliott JD, Lago MA, Cousins RD, Gao A, Leber JD, et al. 1994. 1,3-Diarylindan-2-carboxylic acids, potent and selective non-peptide endothelin receptor antagonists. J. Med. Chem. 37:1553-57
77. 77. Ohlstein EH, Nambi P, Douglas SA, Edwards RM, Gellai M, Lago A. 1994. SB 209670, a rationally designed potent nonpeptide endothelin receptor antagonist. Proc. Natl. Acad. Sci. USA 91:8052-56
78. A receptor antagonist. J. Pharmacol. Exp. Ther. 273:1410-17
79. 79. Williams, DL Jr, Murphy KL, Nolan NA, O'Brien JA, Pettibone JA, et al. 1995. Pharmacology of L-754,142, a highly potent, orally active, nonpeptidyl endothelin antagonist. J. Pharmacol. Exp. Ther. 275:1518-26
80. 80. Krause SM, Walsh TF, Greenlee WJ, Ranaei R, Kivlighn SD. 1995. Renal protection by endothelin antagonist, L-754,142, following aortic cross-clamping in the dog. Circulation 92(Suppl. 1): 1065 (Abstr.)
81. 81. Yamauchi R, Hoshino T, Ban Y, Kikkawa K, Murata S, et al. 1996. Effects of T-0115, a novel orally active endothelin antagonist, on monocrotaline-induced pulmonary hypertension in rats. Jpn. J. Pharmacol. 70(Suppl. 1):236 (Abstr.)
82. 82. Hoshino T, Yamauchi R, Kikkawa K, Yabana H, Murata S. 1998. Pharmacological profile of T-0201, a highly potent and orally active endothelin receptor antagonist. J. Pharmacol. Exp. Ther. 286:643-49
83. B endothelin receptor antagonist. Naunyn Schmiedebergs Arch. Pharmacol. 358(Suppl. 2):511 (Abstr.)
84. A/B endothelin receptor-selective antagonists. J. Cardiovasc. Pharmacol. 26(Suppl. 3):S358-61
85. A receptor antagonist, determined for human endothelin receptors. J. Cardiovasc. Pharmacol. 26(Suppl. 3):S362-64
86. 86. Smith TW, Braunwald E, Kelly RA. 1992. In Heart Disease, ed. E Braunwald, pp. 464-519. Philadelphia, PA: Saunders
87. 87. Ho KK, Pinsky JL, Kannel WB, Levy D. 1993. The epidemiology of heart failure: the Framingham Study. J. Am. Coll. Cardiol. 22:6-13A
88. 88. Ho KK, Anderson KM, Kannel WB, Grossman W, Levy D. 1993. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 88:107-15
89. 89. Pfeffer MA. 1995. Left ventricular remodeling after acute myocardial infarction. Annu. Rev. Med. 46:455-66
90. 90. Kannel WB, Sorlie P, McNamara PM. 1979. Prognosis after initial myocardial infarction: Framingham study. Am. J. Cardiol. 44:53-59
91. 91. Hiroe M, Hirata Y, Fujita N, Umezawa S, Ito H, et al. 1991. Plasma endothelin-1 levels in idiopathic dilated cardiomyopathy. Am. J. Cardiol. 68:1114-15
92. 92. McMurray JJ, Ray SG, Abdullah IA, Dargie HJ, Morton JJ. 1992. Plasma endothelin in chronic heart failure. Circulation 85:1374-79
93. 93. Stewart DJ, Cernacek P, Costello KB, Rouleau JL. 1992. Elevated endothelin-1 in heart failure and loss of normal response to postural change. Circulation 85:510-17
94. 94. Margulies KB, Hildebrand FL Jr, Lerman A, Perrella MA, Burnett JC Jr. 1990. Increased endothelin-1 in experimental heart failure. Circulation 82:2226-30
95. 95. Underwood RD, Aarhus LL, Heublein DM, Burnett JC Jr. 1992. Endothelin in thoracic inferior vena caval constriction model of heart failure. Am. J. Physiol. 263:H951-55
96. 96. Miyauchi T, Yanagisawa M, Tomizawa T, Sugishita Y, Suzuki N, et al. 1989. Increased plasma concentrations of endothelin-1 and big endothelin-1 in acute myocardial infarction. Lancet 2:53-54
97. 97. Sakai S, Miyauchi T, Sakurai T, Kasuya Y, Ihara M, et al. 1996. Endogenous endothelin-1 participates in the maintenance of cardiac function in rats with congestive heart failure. Marked increase in endothelin-1 production in the failing heart. Circulation 93:1214-22
98. 98. Rubanyi GM, Polokoff MA. 1994. Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathology. Pharmacol. Rev. 45:325-415
99. 99. Suzuki T, Kumazaki T, Mitsui Y. 1993. Endothelin-1 is produced and secreted by neonatal rat cardiac myocytes in vitro. Biochem. Biophys. Res. Commun. 193:823-30
100. 100. Goto K, Warner TD. 1995. Endothelin versatility. Nature 375:539-40
101. 101. Miyauchi T, Yorikane R, Sakai S, Sakurai T, Okada M, et al. 1993. Contribution of endogenous endothelin-1 to the progression of cardiopulmonary alterations in rats with monocrotaline-induced pulmonary hypertension. Circ. Res. 73:887-97
102. A receptor antagonist blocks cardiac hypertrophy provoked by hemodynamic overload. Circulation 89:2198-203
103. 103. Shubeita HE, McDonough PM, Harris AN, Knowlton KU, Glembotski CC, et al. 1990. Endothelin induction of inositol phospholipid hydrolysis, sarcomere assembly, and cardiac gene expression in ventricular myocytes. A paracrine mechanism for myocardial cell hypertrophy. J. Biol. Chem. 265:20555-562
104. 104. Stawski G, Olsen UB, Grande P. 1991. Cytotoxic effect of endothelin-1 during 'stimulated' ischaemia in cultured myocytes. Eur. J. Pharmacol. 201:123-24
105. 105. Prasad MR. 1991. Endothelin stimulates degradation of phospholipids in isolated rat hearts. Biochem. Biophys. Res. Commun. 174:952-57
106. 106. Sakai S, Miyauchi T, Kobayashi M, Yamaguchi I, Goto K, Sugishita Y. 1996. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature 384:353-55
107. 107. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, et al for The PROMISE Study Research Group. 1991. Effect of oral milrinone on mortality in severe chronic heart failure. N. Engl. J. Med. 325:1468-75
108. 108. Katz AM. 1986. Potential deleterious effects of inotropic agents in the therapy of chronic heart failure. Circulation 73:III184-88
109. 109. Yorikane R, Koike H. 1990. The arrhythmogenic action of endothelin in rats. Jpn. J. Pharmacol. 53:259-63
110. 110. Emori T, Hirata Y, Ohta K, Shichiri M, Marumo F. 1989. Secretory mechanism of immunoreactive endothelin in cultured bovine endothelial cells. Biochem. Biophys. Res. Commun. 160:93-100
111. 111. Sumpio BE, Widmann MD. 1990. Enhanced production of endothelium-derived contracting factor by endothelial cells subjected to pulsatile stretch. Surgery 108:277-81
112. 112. Ito H, Hirata Y, Adachi S, Tanaka M, Tsujino M, et al. 1993. Endothelin-1 is an autocrine/paracrine factor in the mechanism of angiotensin II-induced hypertrophy in cultured rat cardiomyocytes. J. Clin. Invest. 92:398-403
113. 113. Yorikane R, Sakai S, Miyauchi T, Sakurai T, Sugishita Y, Goto K. 1993. Increased production of endothelin-1 in the hypertrophied rat heart due to pressure overload. FEBS Lett. 332:31-34
114. 114. Reiss K, Capasso JM, Huang H, Meggs LG, Li P, Anversa P. 1993. ANG II receptors, c-myc, and c-jun in myocytes after myocardial infarction and ventricular failure. Am. J. Physiol. 264:H760-69
115. 115. Yanagisawa M, Inoue A, Takuwa Y, Mitsui Y, Kobayashi M, Masaki T. 1989. The human preproendothelin-1 gene: possible regulation by endothelial phosphoinositide turnover signaling. J. Cardiovasc. Pharmacol. 13(Suppl. 5):S13-17
116. 116. Hirata Y, Fukuda Y, Yoshimi H, Emori T, Shichiri M, Marumo F. 1989. Specific receptor for endothelin in cultured rat cardiocytes. Biochem. Biophys. Res. Commun. 160:1438-44
117. 117. Kiowski W, Sutsch G, Hunziker P, Muller P, Kim J, et al. 1995. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet 346:732-36
118. 118. Cody RJ, Haas GJ, Binkley PF, Capers Q, Kelly R. 1992. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation 85:504-9
119. 119. Spinale FG, Walker JD, Mukherjee R, Inannini JP, Keever AT, Gallagher KP. 1997. Concomitant endothelin receptor subtype-A blockade during the progression of pacing-induced congestive heart failure in rabbits. Circulation 95:1918-29
120. 120. Omland T, Lie RT, Aakvaag A, Arsland T, Dickstein K. 1994. Plasma endothelin determination as a prognostic indicator of 1-year mortality after acute myocardial infarction. Circulation 89:1573-79
121. 121. Pacher R, Stanek B, Hulsmann M, Koller Sj, Berger R, et al. 1996. Prognostic impact of big endothelin-1 plasma concentrations compared with invasive hemodynamic evaluation in severe heart failure. J. Am. Coll. Cardiol. 27:633-41
122. 122. Krum H, Gu A, Wilshire CM, Sackner BJ, Goldsmith R, et al. 1996. Changes in plasma endothelin-1 levels reflect clinical response to beta-blockade in chronic heart failure. Am. Heart J. 131:337-41
123. 123. Brezis M, Epstein FH. 1993. Cellular mechanisms of acute ischemic injury in the kidney. Annu. Rev. Med. 44:27-37
124. 124. Nord EP. 1993. Renal actions of endothelin. Kidney Int. 44:451-63
125. 125. Tomita K, Ujiie K, Nakanishi T, Tomura S, Matsuda K, et al. 1989. Plasma endothelin levels in patients with acute renal failure. N. Engl. J. Med. 321:1127
126. 126. Shibouta Y, Suzuki N, Shino A, Matsumoto H, Terashita Z-I, et al. 1990. Pathophysiological role of endothelin in acute renal failure. Life Sci. 46:1611-18
127. 127. Kon V, Yoshioka T, Fogo A, Ichikawa I. 1989. Glomerular actions of endothelin in vivo. J. Clin. Invest. 83:1762-67
128. 128. Lopez-Farre A, Gomez-Garre D, Bernabeu F, Lopez-Novoa M. 1991. A role for endothelin in the maintenance of postischemic renal failure in the rat. J. Physiol. 444:513-22
129. 129. Vemulapalli S, Chiu PJS, Chintala M, Bernardino V. 1993. Attenuation of ischemic acute renal failure by phosphoramidon in rats. Pharmacology 47:188-90
130. 130. Mino N, Kobayashi M, Nakajima A, Amano H, Shimamoto K, et al. 1992. Protective effect of a selective endothelin receptor antagonist, BQ-123, in ishemic acute renal failure in rats. Eur. J. Pharmacol. 221:77-83
131. 131. Gellai M, Jugus M, Fletcher T, DeWolf R, Nambi P. 1994. Reversal of postischemic acute renal failure with a selective endothelin A receptor antagonist in the rat. J. Clin. Invest. 93:900-6
132. 132. Kopp J, Klotmann PE. 1990. Cellular and molecular mechanisms of cyclosporin nephrotoxicity. J. Am. Soc. Nephrol. 1:162-70
133. 133. Kon V, Sugiura M, Inagami T, Harvie BR, Ichikawa I, Hoover RL. 1990. Role of endothelin in cyclosporin induced glomerular dysfunction. Kidney Int. 37:1487-91
134. 134. Kon V, Badr KF. 1991. Biological actions and pathophysiological significance of endothelin in the kidney. Kidney Int. 40:1-12
135. 135. Kon V, Awazu M. 1992. Endothelin and cyclosporin nephrotoxicity. Ren. Fail. 14:345-50
136. 136. Perico N, Dadan J, Remuzzi G. 1990. Endothelin mediates the renal vasoconstriction induced by cyclosporin in the rat. J. Am. Soc. Nephrol. 1:76-83
137. 137. Awazu M, Sugiura M, Inagami T, Ichikawa I, Kon V. 1990. Cyclosporin promotes glomerular endothelin binding in vivo. J. Am. Soc: Nephrol. 1:1253-58
138. 138. Brooks DP, Ohlstein EH, Contino LC, Storer B, Pullen M, et al. 1991. Effect of nifedipine on cyclosporin A-induced nephrotoxicity, urinary endothelin excretion and renal endothelin receptor number. Eur. J. Pharmacol. 194:115-17
139. 139. Fogo F, Hellings SE, Inagami T, Kon V. 1992. Endothelin receptor antagonism is protective in in vivo acute cyclosporin toxicity. Kidney Int. 42:770-74
140. 140. Bloom ITM, Bertley FR, Garrison RN. 1993. Acute cyclosporine-induced renal vasoconstriction is mediated by endothelin-1. Surgery 114:480-88
141. 141. Takahashi K, Totsune K, Mouri T. 1994. Endothelin in chronic renal failure. Nephron 66:373-79
142. 142. Haynes WG, Ferro CJ, O'Kane KPJ, Somerville D, Lomax CC, Webb DJ. 1996. Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans. Circulation 93:1860-70
143. 143. Hirata Y, Takagi N, Fukuda Y, Marumo F. 1989. Endothelin is a potent mitogen for rat vascular smooth muscle cells. Atherosclerosis 78:225-28
144. A receptor in the maintenance of deoxycorticosterone acetate-salt-induced hypertension. Br. J. Pharmacol. 114:925-30
145. 145. Verma S, Bhanot S, Mcneill LH. 1995. Effect of chronic endothelin blockade in hyperinsulinemic hypertensive rats. Am. J. Physiol. 269:H2017-21
146. 146. Warner TD, Allcock GH, Vane JR. 1994. Reversal of established responses to endothelin-1 in vivo and in vitro by the endothelin receptor antagonists, BQ123 and PD145065. Br. J. Pharmacol. 112:207-13
147. 147. Matsumura Y, Fujita K, Miyazaki Y, Takaoka M, Morimoto S. 1995. Involvement of endothelin-1 in deoxycorticosterone acetate-salt-induced hypertension and cardiovascular hypertrophy. J. Cardiovasc. Pharmacol. 26(Suppl. 3):S456-58
148. 148. Vemulapalli S, Watkins RW, Brown A, Cook J, Bernardino V, Chiu PJ. 1993. Disparate effects of phosphoramidon on blood pressure in SHR and DOCA-salt hypertensive rats. Life Sci. 53:783-93
149. 149. Nishikibe M, Tsuchida S, Okada M, Fukuroda T, Shimamoto K, Yano M. 1993. Antihypertensive effects of a newly synthesized endothelin antagonist, BQ123, in a genetic hypertensive model. Life Sci. 52:717-24
150. A receptor antagonist. J. Pharmacol. Exp. Ther. 264:1040-46
151. 151. Ohlstein EH, Douglas SA, Ezekiel M, Gellai M. 1993. Antihypertensive effects of the endothelin antagonist BQ-123 in conscious spontaneously hypertensive rats. J. Cardiovasc. Pharmacol. 22(Suppl. 8):S321-24
152. 152. Donckier J, Stoleru L, Hayashida W, Van-Mechelen H, Selvais P, et al. 1995. Role of endogenous endothelin-1 in experimental renal hypertension in dogs. Circulation 92:106-13
153. 153. Gardiner SM, March JE, Kemp PA, Mullins JJ, Bennett T. 1995. Haemodynamic effects of losartan and the endothelin antagonist, SB209670, in conscious, transgenic ((mRen-2) 27), hypertensive rats. Br. J. Pharmacol. 116:2237-44
154. 154. Mullins JJ, Peters J, Ganten D. 1990. Fluminent hypertension in transgenic rats harbouring the mouse Ren-2 gene. Nature 344:541-44
155. 155. Webb DJ, Monge JC, Rabelink TJ, Yanagisawa M. 1998. Endothelin: new discoveries and rapid progress in the clinic. Trends Pharmacol. Sci. 19:5-8
156. 156. Battistini B, D'Orleans-Juste P, Sirois P. 1993. Biology of diseases, endothelin: circulating plasma levels and presence in other biological fluids. Lab. Invest. 6:600-28
157. 157. Krum H, Viskoper RJ, Lacourciere Y, Budde M, Charlon V. 1998. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. N. Engl. J. Med. 338:784-90
158. 158. Findlay JM, Weir BKA, Kanamaru K, Epinosal F. 1989. Arterial wall changes in cerebral vasospasm. Neurosurgery 25: 736-46
159. 159. Asano T, Ikegaki I, Suzuki S, Shibuya M. 1989. Endothelin and the production of cerebral vasospasm in dogs. Biochem. Biophys. Res. Commun. 159:1345-13
160. 160. Mima T, Yanagisawa M, Shigeno T, Saito A, Goto K, et al. 1989. Endothelin acts in feline and canine cerebral arteries from the adventitial side. Stroke 20:1553-56
161. 161. Masaoka H, Suzuki R, Hirata Y, Emori T, Marumo F, Hirakawa K. 1990. Raised plasma endothelin in aneurysmal subarachnoid haemorrhage. Lancet 2:1402
162. 162. Fujimori A, Yanagisawa M, Saito A, Goto K, Masaki T, et al. 1990. Endothelin in plasma and cerebrospinal fluid of patients with subarachnoid hemorrhage. Lancet 336:633
163. 163. Suzuki H, Sato S, Suzuki Y, Oka M, Tsuchiya T, et al. 1990. Endothelin immunoreactivity in cerebrospinal fluid of patients with subarachnoid haemorrhage. Ann. Med. 22:233-36
164. 164. Kraus GE, Bucholz RD, Yook KW, Kneupfer MM, Smith KR. 1991. Cerebrospinal fluid endothelin-1 and endothelin-3 levels in normal and neurosurgical patients: a clinical study and literature review. Surg. Neurol. 35:20-29
165. 165. Shigeno T, Mima Y, Yanagisawa M, Saito A, Goto K, et al. 1991. Prevention of cerebral vasospasm by actinomysin D. J. Neurosurg. 74:940-43
166. A receptor mRNA expression in a canine subrachnoid hemorrhage model. J. Neurosurg. 81:759-64
167. 167. Alabadi JA, Salom JB, Torregross G, Miranda FJ, Jover T, Alborch E. 1993. Changes in the cerebrovascular effects of endothelin-1 and nicardipine after experimental subarachnoid hemorrhage. Neurosurgery 33:707-15
168. A receptor antagonist, FR139317, ameliorates cerebral vasospasm in dogs. Life Sci. 49:1869-74
169. 169. Matsumura Y, Ikegawa R, Suzuki Y, Takaoka M, Uchida T, et al. 1991. Phosphoramidon prevents cerebral vasospasm following subarachinoid hemorrhage in dogs: the relationship to endothelin-1 levels in the cerebrospinal fluid. Life Sci. 49:841-48
170. 170. Hirose H, Ide K, Sakaki T, Takahashi R, Kobayashi M, et al. 1995. The role of endothelin and nitric oxide in modulation of normal and spastic cerebral vascular tone in the dog. Eur. J. Pharmacol. 277:77-87
171. 171. Willette RN, Zhang H, Mitchell MP, Sauermelch CF, Ohlstein EH, Sulpizio AC. 1994. Nonpeptide endothelin antagonist: cerebrovascular characterization and effects on delayed cerebral vasospasm. Stroke 25:2450-56
172. 172. Shigeno T, Clozel M, Sakai S, Saito A, Goto K. 1995. The effect of bosentan, a new potent endothelin receptor antagonist, on the pathogenesis of cerebral vasospasm. Neurosurgery 37:87-91
173. 173. Heath D, Smith P, Gosney J, Mulcahy D, Fox K, et al. 1987. The pathology of the early and late stages of primary-pulmonary hypertensin. Br. Heart J. 58: 204-13
174. 174. Cernacek P, Stewart DJ. 1989. Immunoreactive endothelin in human plasma: marked elevations in patients in cardiogenic shock. Biochem. Biophys. Res. Commun. 161:562-67
175. 175. Yoshibayashi M, Nishioka K, Nakao K, Saito Y, Matusmura M, et al. 1991. Plasma endothelin concentrations in patients with pulmonary hypertension associated with congenital heart defects: evidence for increased production of endothelin in pulmonary Circulation 84:2280-85
176. 176. Cacoub P, Dorent R, Maistre G, Nataf P, Carayon A, et al. 1993. Endothelin-1 in primary pulmonary hypertension and the Eisenmenger syndrome. Am. J. Cardiol. 71:448-50
177. 177. Ishikawa S, Miyauchi T, Ueno H, Ushinohama H, Sagawa K, et al. 1995. Influence of pulmonary blood pressure and flow on endothelin-1 production in humans. J. Cardiovasc. Pharmacol. 26:429-33
178. 178. Ishikawa S, Miyauchi T, Sakai S, Ushinohama H, Sagawa K, et al. 1995. Elevated levels of plasma endothelin-1 in young patients with pulmonary hypertension caused by congenital heart disease are decreased after successful surgical repair. J. Thorac. Cardiovasc. Surg. 110:271-73
179. 179. Giaid A, Yanagisawa M, Langleben D, Michel RP, Levy R, et al. 1993. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N. Engl. J. Med. 328:1732-39
180. 180. Giaid A, Michel RP, Stewart DJ, Sheppard M, Corrin B, Hamid Q. 1993. Expression of endothelin-1 in lungs of patients with crystogenic fibrosing alveolitis. Lancet 341:1550-54
181. 181. Stelzner TJ, O'Brien RF, Sato K, Webb S, Zamora MR, et al. 1992. Increased endothelin-1 expression in rats with pulmonary hypertension. Am. J. Physiol. 262:L614-20
182. 182. Zamora MR, Stelzner TJ, Webb S, Panos RJ, Ruff LJ, Dempsey EC. 1996. Overexpression of endothelin-1 and enhanced growth of pulmonary artery smooth muscle cell from fawn-fooded rats. Am. J. Physiol. 270:L101-9
183. 183. Cassis LA, Rippetoe PA, Soltis EE, Painter DJ, Fitz R, Gillespie MN. 1992. Angiotensin II and monocrotaline-induced pulmonary hypertension: effect of losartan (DuP753), a nonpeptide angiotensin type I receptor antagonist. J. Pharmacol. Exp. Ther. 262:1168-72
184. 184. Okada M, Yamashita C, Okada M, Okada K. 1995. Role of endothelin-1 in beagles with dehydromonocrotaline-induced pulmonary hypertension. Circulation 92:114-19
185. 185. Eddahibi S, Raffenstin B, Clozel M, Levame M, Adnot S. 1995. Protection from pulmonary hypertension with an orally active endothelin receptor antagonist in hypoxic rats. Am. J. Physiol. 268:H828-35
186. 186. Sakai S, Miyauchi T, Sakurai T, Yamaguchi I, Kobayashi M, et al. 1996. Pulmonary hypertension caused by congestive heart failure is markedly ameliorated by chronic application of an endothelin receptor antagonist: increased expression of endothelin-1 mRNA and endothelin-1-like immunoreactivity in the lung in congestive heart failure in rats. J. Am. Coll. Cardiol. 28:1580-88